Is MRD Negativity the End Goal? Understanding When/Why It's Important image

Is MRD Negativity the End Goal? Understanding When/Why It's Important

Feb 23, 2023
07:00PM - 08:00PM EST
Online Event
Overview

Many of you are familiar with the basic concept of MRD, and perhaps some feel the "pressure" to get to MRD negativity. But should all regimens' end goal be to achieve MRD negativity? And if MRD negativity is not achieved with the initial treatment, but the patient is in complete response, should the therapy be adjusted to achieve MRD negativity? This type of question will be answered by myeloma specialist, Dr. Marc Braunstein. Join us as we learn together.

Agenda
07:00 PM
Introductions
Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr.  Marc Braunstein.

07:05 PM
Presentation
Marc Braunstein, MD, PhD

Dr. Marc Braunstein talks about MRD negativity.

07:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Marc Braunstein, MD, PhD

Marc Braunstein, MD, PhD

Marc Braunstein, MD, PhD is a board-certified hematologist/oncologist with a long-standing interest in plasma cell disorders. He is a part of the NYU Perlmutter Cancer Center's multiple myeloma and cellular therapy programs and serve as Associate Professor of Medicine at NYU Grossman Long Island School of Medicine where he co-direct the medical school hematology curriculum and also serves as Director of the hematology/oncology fellowship program. His clinical research focus is on the use of novel immunotherapy combinations to treat multiple myeloma. As part of his role, he also focuses on medical education and serves on education committees for the American Society of Hematology and American Society of Clinical Oncology, as well as volunteer committees with the American Society of Clinical Oncology and American College of Physicians. In his free time he volunteers with the Leukemia and Lymphoma Society, spends time with his family, and enjoys playing guitar and mandolin.